Update on HIV lipodystrophy.
When prescribed appropriately and taken adherently, antiretroviral therapy can consistently and durably suppress HIV replication, potentially translating into years of near normal health for HIV-infected persons. However, presently available antiretrovirals are associated with a cluster of physical and metabolic symptoms termed HIV lipodystrophy. This article reviews the state of knowledge about the pathogenesis and treatment of the various manifestations of these adverse effects.
Kravcik
Stephen
S
Department of Medicine, Ottawa Hospital/University of Ottawa, 501 Smyth Road, Ottawa, Ontario, Canada K4M 1K3. skravcik@ottawahospital.on.ca
D019380:Anti-HIV Agents / Q000009:adverse effects*; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D008060:Lipodystrophy / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control
D019380:Anti-HIV Agents